naa a22 4500 510764053 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130401xx s 000 0 eng 10.1007/s12094-012-0921-0 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0921-0 Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer [Elektronische Daten] [Muharrem Bayrak, Omer Olmez, Ender Kurt, Erdem Cubukcu, Turkkan Evrensel, Ozkan Kanat, Osman Manavoglu] Background: Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer. Methods: Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures. Results: c-erbB2 was overexpressed in 19 (41.3%) cases and 8 patients (17.4%) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in >10% of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48±1.03months, whereas the mean TTP was 8.28±0.8months. Compared with patients with a score of 2+or less (n=38), those with a c-erbB2 score of 3+(n=8) had both a significantly lower OS (15.55±1.63 vs. 8.22±0.88months, respectively, p<0.05) and TTP (10.72±1.81 vs. 6.11±0.61months, respectively, p<0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio=1.9; 95% confidence interval=1.1−3.7, p<0.05) and TTP (hazard ratio=1.8; 95% confidence interval=1.1−4.1, p<0.05). Conclusion: Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer. Federación de Sociedades Españolas de Oncología (FESEO), 2012 c-erbB2 nationallicence Gastric cancer nationallicence Metastasis nationallicence Immunohistochemistry nationallicence Prognosis nationallicence Bayrak Muharrem Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Olmez Omer Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Kurt Ender Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Cubukcu Erdem Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Evrensel Turkkan Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Kanat Ozkan Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Manavoglu Osman Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut Clinical and Translational Oncology Springer Milan 15/4(2013-04-01), 307-312 1699-048X 15:4<307 2013 15 12094 https://doi.org/10.1007/s12094-012-0921-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0921-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bayrak Muharrem Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 700 1- Olmez Omer Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 700 1- Kurt Ender Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 700 1- Cubukcu Erdem Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 700 1- Evrensel Turkkan Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 700 1- Kanat Ozkan Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 700 1- Manavoglu Osman Department of Medical Oncology, Uludag University Medical School, 16059, Bursa, Turkey aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/4(2013-04-01), 307-312 1699-048X 15:4<307 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer